- Home
- BUJA vs BIVI Comparison
BUJA vs BIVI Comparison
Compare BUJA & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- BIVI
- Stock Information
- Founded
- BUJA 2022
- BIVI 2013
- Country
- BUJA Malaysia
- BIVI United States
- Employees
- BUJA N/A
- BIVI N/A
- Industry
- BUJA Blank Checks
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- BUJA Finance
- BIVI Health Care
- Exchange
- BUJA Nasdaq
- BIVI Nasdaq
- Market Cap
- BUJA 54.3M
- BIVI 45.1M
- IPO Year
- BUJA 2023
- BIVI N/A
- Fundamental
- Price
- BUJA $10.99
- BIVI $3.19
- Analyst Decision
- BUJA
- BIVI Strong Buy
- Analyst Count
- BUJA 0
- BIVI 2
- Target Price
- BUJA N/A
- BIVI $40.00
- AVG Volume (30 Days)
- BUJA 4.1K
- BIVI 14.4M
- Earning Date
- BUJA 01-01-0001
- BIVI 11-13-2024
- Dividend Yield
- BUJA N/A
- BIVI N/A
- EPS Growth
- BUJA N/A
- BIVI N/A
- EPS
- BUJA N/A
- BIVI N/A
- Revenue
- BUJA N/A
- BIVI N/A
- Revenue This Year
- BUJA N/A
- BIVI N/A
- Revenue Next Year
- BUJA N/A
- BIVI N/A
- P/E Ratio
- BUJA $30.09
- BIVI N/A
- Revenue Growth
- BUJA N/A
- BIVI N/A
- 52 Week Low
- BUJA $10.32
- BIVI $1.04
- 52 Week High
- BUJA $12.18
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- BUJA 66.75
- BIVI 61.79
- Support Level
- BUJA $10.95
- BIVI $2.87
- Resistance Level
- BUJA $10.98
- BIVI $3.61
- Average True Range (ATR)
- BUJA 0.00
- BIVI 0.35
- MACD
- BUJA -0.00
- BIVI 0.05
- Stochastic Oscillator
- BUJA 100.00
- BIVI 67.19
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.